CD274 and head and neck squamous cell carcinoma: In recent years, there has also been a rise in concern about the use of immune checkpoint inhibitors, which target the programmed death-ligand 1 (PD-L1) and other immune-suppressing proteins, as therapeutic options for HNSCC [3].